title: Genetically engineered T-cells for adoptive immunotherapy.
abstract: Adaptive immunotherapy with T-cells is being evaluated as therapy for a number of malignancies and viral infections. Genetic modification of infused T-cells has been used for several years to track such cells, to redirect and augment the immune response towards tumors, and to provide a means of ablating infused T-cells should adverse effects occur. New strategies to target T-cells to tumors and to genetically modify them to make them resistant to tumor evasion mechanisms are being evaluated in preclinical models.
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: Martin
authors.initials: M
authors.lastname: Pule
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
authors.forename: Helen E
authors.initials: HE
authors.lastname: Heslop
mesh_terms: D005818:Genetic Engineering; D006801:Humans; D016219:Immunotherapy, Adoptive; D013601:T-Lymphocytes / Q000276:immunology*